Special Issue

Cardiomyopathy and Precision Medicine

Message from the Guest Editor

The diagnosis of the most common forms of cardiomyopathies, dilated and hypertrophic cardiomyopathies, have long been based on morphology and function by non-invasive diagnostic modalities (e.g., echocardiography). In addition, despite extensive studies on biophysical, cellular, and animal models, the current approaches to the management of patients with cardiomyopathies remain largely unchanged. Recent advances in genetics, proteomics, metabolomics, and microbiomics broadened our understanding of the molecular and cellular pathophysiology of cardiovascular diseases including cardiomyopathies, which can potentially lead to more precise risk prediction and the discovery of the optimal treatment strategies for individual patient. Also, novel approaches such as artificial intelligence and machine learning to medical big data from various sources includng clinical registries, electronic health records, biomarkers, medical images, and all spectrum of 'omics' data (e.g., genomic, proteomic, and metabolomic data) have a huge potential of empowering personalized medicine for cardiomyopathy patients.

Guest Editor

Dr. Yuji Nagatomo
Department of Cardiology, National Defense Medical College, Tokorozawa, Saitama 359, Japan

Deadline for manuscript submissions

closed (31 July 2022)

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

mdpi.com/si/81747

Journal of Personalized Medicine
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed

mdpi.com/journal/jpm

MDPI

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (*JPM*; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri
1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA
2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).